top of page
Browse by category
Search


GLP-1s associated with higher risk of major depression, increased risk for anxiety and an elevated risk for suicidal behaviour
Patients on glucagon-like peptide-1 receptor agonists (GLP-1 RAs) - Victoza (Liraglutide 1.8mg), Saxenda (Liraglutide 3mg), Ozempic...


STEP 9: Semaglutide reduces knee osteoarthritis-related pain in people with obesity
Results from STEP 9 phase 3 clinical trial shows that studied semaglutide 2.4mg, compared to placebo as an adjunct to lifestyle...


Semaglutide has positive effect in chronic kidney disease
Semaglutide has a positive effect on patients with chronic kidney disease and obesity. By decreasing the amount of protein in urine, the...


Semaglutide improves skin condition hidradenitis suppurative in people living with obesity
Semaglutide has demonstrated a significant potential in treating hidradenitis suppurative (HS), a common and chronic skin condition, in...

Journal watch 18/09/2024
Welcome to our weekly round-up of the latest bariatric and obesity-related papers published in the medical literature. As ever, we have...


Key factors that can impact long-term weight loss in patients with obesity prescribed GLP-1 RA medications
Weight reduction at one year is associated with the injectable semaglutide or liraglutide’s active agent, its dosage, treatment...


Semaglutide cardiovascular benefits are maintained in people with impaired kidney function
Semaglutide may help to prevent heart attacks, strokes, and other major adverse cardiovascular events (MACE) as well as death in adults...

Semaglutide hydrogel could reduce diabetes shots to once a month
French researchers have developed a new drug delivery system that could cut the dosing schedule for type 2 diabetes and weight control...

No increased risk of mental health issues among those using semaglutide for weight loss
Taking the weight loss medication semaglutide does not increase the risk of depressive symptoms, suicidal thoughts or suicidal behaviour...


Semaglutide reduces COVID-19 related deaths in patients with obesity and CVD
Semaglutide reduced the rates of COVID-19-related adverse events, including death, in those who had overweight or obesity and established...
Browse by tag




bottom of page